JAC Advance Access originally published online on May 29, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 2-4
© 2003 The British Society for Antimicrobial Chemotherapy
Leading Article |
AmpC ß-lactamases: what do we need to know for the future?
Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
Keywords: AmpC, ß-lactamase
| The first 150 words of the full text of this article appear below. |
AmpC ß-lactamases have been a target of study since the late 1970s. Most of these enzymes are cephalosporinases but are capable of hydrolysing all ß-lactams to some extent.1,2 Researchers have examined characteristics of both inducible and non-inducible AmpC ß-lactamases such as physical properties, hydrolytic activity, the molecular mechanisms involved in chromosomal expression, and comparative studies between genera on the induction potential of the enzyme.1,3 In the late 1980s, these inducible chromosomal genes were detected on plasmids (most without induction capabilities) and were transferred to organisms, which typically do not express these types of ß-lactamase such as Klebsiella spp., Escherichia coli, or Salmonella spp. The plasmid-encoded or ‘imported’ ampC ß-lactamase complicates the job of clinical microbiologists working in hospital laboratories. No longer can a Gram-negative organism be considered a potential AmpC-producing organism based on identification. In addition, many clinical microbiologists are unaware of plasmid-encoded AmpC ß-lactamases because phenotypic detection is
 |
Molecular aspects |
|---|
|
Clinical implications of plasmid-encoded AmpC-mediated resistance |
|---|
|
Acknowledgements |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. P. Baughman The Use of Carbapenems in the Treatment of Serious Infections J Intensive Care Med, July 1, 2009; 24(4): 230 - 241. [Abstract] [PDF]
|
|
|
|
 |
|
 D. McIntosh, M. Cunningham, B. Ji, F. A. Fekete, E. M. Parry, S. E. Clark, Z. B. Zalinger, I. C. Gilg, G. R. Danner, K. A. Johnson, et al. Transferable, multiple antibiotic and mercury resistance in Atlantic Canadian isolates of Aeromonas salmonicida subsp. salmonicida is associated with carriage of an IncA/C plasmid similar to the Salmonella enterica plasmid pSN254 J. Antimicrob. Chemother., June 1, 2008; 61(6): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mammeri, L. Poirel, N. Fortineau, and P. Nordmann Naturally Occurring Extended-Spectrum Cephalosporinases in Escherichia coli. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2573 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Padilla, D. Alonso, A. Domenech-Sanchez, C. Gomez, J. L. Perez, S. Alberti, and N. Borrell Effect of Porins and Plasmid-Mediated AmpC {beta}-Lactamases on the Efficacy of {beta}-Lactams in Rat Pneumonia Caused by Klebsiella pneumoniae. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2258 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. D'Andrea, E. Nucleo, F. Luzzaro, T. Giani, R. Migliavacca, F. Vailati, V. Kroumova, L. Pagani, and G. M. Rossolini CMY-16, a Novel Acquired AmpC-Type {beta}-Lactamase of the CMY/LAT Lineage in Multifocal Monophyletic Isolates of Proteus mirabilis from Northern Italy Antimicrob. Agents Chemother., February 1, 2006; 50(2): 618 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Song, E. S. Moland, N. D. Hanson, J. S. Lewis, J. H. Jorgensen, and K. S. Thomson Failure of Cefepime Therapy in Treatment of Klebsiella pneumoniae Bacteremia J. Clin. Microbiol., September 1, 2005; 43(9): 4891 - 4894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yagi, J.-i. Wachino, H. Kurokawa, S. Suzuki, K. Yamane, Y. Doi, N. Shibata, H. Kato, K. Shibayama, and Y. Arakawa Practical Methods Using Boronic Acid Compounds for Identification of Class C {beta}-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli J. Clin. Microbiol., June 1, 2005; 43(6): 2551 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Mulvey, E. Bryce, D. A. Boyd, M. Ofner-Agostini, A. M. Land, A. E. Simor, S. Paton, the Canadian Hospital Epidemiology Committee, and the Canadian Nosocomial Infection Surveillance Pro Molecular Characterization of Cefoxitin-Resistant Escherichia coli from Canadian Hospitals Antimicrob. Agents Chemother., January 1, 2005; 49(1): 358 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sturenburg, M. Lang, M. A. Horstkotte, R. Laufs, and D. Mack Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum {beta}-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria J. Antimicrob. Chemother., November 1, 2004; 54(5): 870 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mammeri, H. Nazic, T. Naas, L. Poirel, S. Leotard, and P. Nordmann AmpC {beta}-Lactamase in an Escherichia coli Clinical Isolate Confers Resistance to Expanded-Spectrum Cephalosporins Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4050 - 4053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Black, K. S. Thomson, and J. D. D. Pitout Use of {beta}-Lactamase Inhibitors in Disk Tests To Detect Plasmid-Mediated AmpC {beta}-Lactamases J. Clin. Microbiol., May 1, 2004; 42(5): 2203 - 2206. [Abstract] [Full Text] [PDF]
|
|